COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Safety Study of Oral ZSTK474 in Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01280487
Recruitment Status : Completed
First Posted : January 20, 2011
Last Update Posted : January 16, 2015
Information provided by (Responsible Party):
Zenyaku Kogyo Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: ZSTK474 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
Study Start Date : January 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : January 2014

Arm Intervention/treatment
Experimental: Oral ZSTK474
Daily oral dosing for 21 days per cycle
Drug: ZSTK474
Daily oral dosing for 21 days each cycle

Primary Outcome Measures :
  1. Maximum tolerated dose [ Time Frame: 21 days ]

Secondary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: 21 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or females ≥18 years of age;
  2. Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for which available therapy is not effective;
  3. ECOG performance status score of ≤2 and an expected survival of >8 weeks;
  4. Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer therapies; all toxicities must be determined to be below Grade 2 (assessed using the NCI CTCAE v4.0).
  5. Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil count (ANC) >1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);
  6. Subjects who are willing and able to provide written informed consent.

In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory biopsies of tumor tissue twice during the first cycle (before and during dosing) and must have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding;
  2. Men or women of reproductive potential who are not willing to use acceptable means of contraception while on study drug and for an additional 90 days after the last dose of study drug;
  3. Body Mass Index (BMI) is ≥30 kg/m2;
  4. Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled (i.e., if CNS lesions have been stable in size for at least one month and the subject is off steroid and anti-convulsants).
  5. Have received any investigational interventional agents within the 4 weeks prior to the start of dosing with ZSTK474;
  6. Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or have received any of these non-investigational agents within the previous 4 weeks or 5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;
  7. Are not able or willing to comply with the study procedures, including the study visit schedule;
  8. Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;
  9. Have serious or significant intercurrent illnesses or underlying diseases, such as:

    1. Diabetes
    2. Gastrointestinal disorder
    3. Hepatic: AST or ALT >2.5 x ULN (or >5.0 x ULN with liver metastases) or serum bilirubin >1.5 x ULN;
    4. Renal (acute or chronic renal disease or eGFR <55 mL/min)
    5. Cardiovascular:

      • Uncontrolled hypertension or blood pressure >140/90 mmHg;
      • Symptomatic congestive heart failure;
      • Myocardial infarction within the past 6 months;
      • Unstable angina pectoris;
      • Cardiac arrhythmia;
      • Congenital long QT syndrome;
      • QTc >450 msec for men or >470 msec for women.
    6. Other:

      • Known diagnosis of HIV infection;
      • Other ongoing or active infections;
      • Psychiatric illness, substance abuse or social situation that would preclude study compliance.
      • Other serious concurrent illness that would preclude assessment of drug effect;
      • PT/PTT)/APTT/INR >ULN for subjects not on anti-coagulants; INR > 1.5 x ULN for subjects on low dose warfarin.
  10. Current treatment with the following drugs:

    • any anti-seizure medications;
    • therapeutic anti-coagulant doses of warfarin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01280487

Layout table for location information
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States
United States, Missouri
Washington University
St Louis, Missouri, United States
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
Zenyaku Kogyo Co., Ltd.
Layout table for investigator information
Principal Investigator: Craig Lockhart, MD Washington University School of Medicine
Principal Investigator: Anthony Olszanski, MD Fox Chase Cancer Center
Principal Investigator: Geoffrey Shapiro, MD PhD Dana-Farber Cancer Institute
Layout table for additonal information
Responsible Party: Zenyaku Kogyo Co., Ltd. Identifier: NCT01280487    
Other Study ID Numbers: ZSTK474-101
First Posted: January 20, 2011    Key Record Dates
Last Update Posted: January 16, 2015
Last Verified: January 2015
Keywords provided by Zenyaku Kogyo Co., Ltd.:
PI3K inhibitor